The Health Emergency Preparedness and Response Authority (HERA) of the European Commission (EC) has entered a co-procurement framework contract for HIPRA HUMAN HEALTH’s bivalent recombinant protein Covid-19 vaccine.
A total of 14 member states and countries are participating in this deal and can procure up to 250 million vaccine doses.
Once the HIPRA vaccine receives a positive assessment from the European Medicines Agency (EMA), this contract will aid in making the doses available rapidly to the participating nations.
The latest contract complements a wide-ranging portfolio of vaccines obtained through the EU Vaccines Strategy, including deals entered with Sanofi–GSK, AstraZeneca, Janssen Pharmaceutica NV, Moderna, Novavax, Pfizer-BioNTech and Valneva.
Under this strategy, the EU has procured nearly 4.2 billion doses of Covid-19 vaccines.
This broad vaccine portfolio will guarantee that Europe is well-equipped for Covid-19 inoculation by utilising vaccines that are shown to be safe and effective.
Furthermore, participating countries could donate the shots to lower and middle-income nations or re-route them to other countries in Europe.
Presently under the rolling review process of the EMA, the HIPRA vaccine is being advanced as a booster in priorly inoculated people aged 16 years and above.
As the vaccine can be stored at refrigerated temperatures of 2 °C to 8°C, it could be stored and supplied in Europe and across the globe.
European Commissioner for Health and Food Safety Stella Kyriakides said: “The HIPRA vaccine adds yet another option to complement our broad vaccine portfolio for our Member States and citizens.
“An increase in vaccination and boosting is essential over the coming months. We are working tirelessly to make sure there are vaccines available for all.”